iShares Biotechnology ETF
897 hedge funds and large institutions have $5.97B invested in iShares Biotechnology ETF in 2022 Q4 according to their latest regulatory filings, with 139 funds opening new positions, 257 increasing their positions, 288 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
897
Holders Change
+73
Holders Change %
+8.86%
% of All Funds
14.47%
Holding in Top 10
22
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+57.14%
% of All Funds
0.35%
New
139
Increased
257
Reduced
288
Closed
44
Calls
$325M
Puts
$511M
Net Calls
-$186M
Net Calls Change
+$278M
Top Buyers
| 1 |
CANY
Caxton Associates (New York)
New York
|
+$152M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$139M |
| 3 |
E
Ergoteles
New York
|
+$87.2M |
| 4 |
Goldman Sachs
New York
|
+$73.5M |
| 5 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$52.5M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$78.5M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$59.7M |
| 3 |
Barclays
London,
United Kingdom
|
-$51.2M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$50.2M |
| 5 |
MMEA
Main Management ETF Advisors
San Francisco,
California
|
-$20.8M |
